Promomed launches the innovative import-substituting drug Enligria for the treatment of overweight and obesity

Promomed Group of Companies, one of the leaders of the Russian pharmaceutical market, announces the launch of the first domestic drug of the glutid group (glucagon-like peptide receptor agonists) for the treatment of overweight and obese patients, as well as for the prevention of the development of cardiovascular complications associated with these diseases.

The new line includes the drugs Enligria, Quinliro (INN liraglutide) and Quincenta (INN semaglutide). The drug under the trade name "Enligria", produced in the form of a pre-filled pen syringe, received a registration certificate the day before. Enligria will be delivered to pharmacies in the second decade of October this year. The drugs "Quinliro" and "Quincenta" are at the stage of state registration.

Liraglutide is one of the most powerful stimulants of insulin production, which makes it possible to achieve stable control of blood sugar levels. The drug also slows down digestion, which helps to avoid sudden spikes in sugar after eating. Thanks to this, diabetic patients can achieve stable blood sugar control and improve their quality of life. It is important to note that liraglutide can be used as an independent medicine or in combination with other drugs, depending on the patient's specific situation. This provides doctors with more opportunities to take an individual approach to treatment and achieve optimal results.

Enligria is a liraglutide produced by chemical synthesis, which is 97% homologous in amino acid composition to human GLP–1, resistant to degradation, therefore it has a long plasma half-life of 13 hours, which makes it possible to use it once a day. The use of the drug leads to a more significant effect on the center of hunger and satiety, which allows you to reduce weight by increasing the feeling of satiety, reducing hunger and the expected amount of food intake.

In the course of the conducted studies, it has been proven that liraglutide 3 mg has an optimal efficacy and safety profile for the treatment of obesity, which is confirmed by data from randomized clinical trials and studies of real clinical practice. The release of domestic GLP agonists, Enligria, Quinliro (liraglutide) and Quincenta (semaglutide) drugs, will make it possible to close the shortage of similar drugs in the country in 2022, associated with the cessation of supplies from a single manufacturer.

Ivan Dedov, Academician of the Russian Academy of Sciences, President of the Federal State Budgetary Institution NMC of Endocrinology of the Ministry of Health of the Russian Federation:
"The problem of overweight affects half of the population of our country, and more than 30 million are obese – a key risk factor for the development of disabling diseases and life-threatening conditions (heart attacks, strokes and other cardiovascular complications). Being overweight also reduces reproductive health and poses a threat to the country's reproductive potential. Reducing the risks caused by impaired metabolic health is possible only by reducing excess weight. And now doctors have in their arsenal a wide range of domestic drugs for personalized treatment of each individual patient.".

Peter Bely, Chairman of the Board of Directors of Promomed Group of Companies:
"The decision to start developing a group of drugs based on glutides was a completely logical and natural step for our team, because we have been working in the field of endocrinology for many years, and the development of this drug was carried out in close collaboration with leading endocrinologists in the country. Our strategy is based on maximum support for national drug safety. Our goal is to provide every Russian patient with innovative, highly effective and affordable drugs as soon as possible. The result achieved today is a long–term systematic work in the field of developing new technologies for the full production cycle of high-demand and vital medicines for the Russian market.".

In order to strengthen the internal cooperation of Russian manufacturers, during import substitution, Promomed produces these new drugs in partnership with the pharmaceutical company "Plant "Medsintez" LLC.

The creation of domestic drugs for the treatment of obesity has been a priority for Promomed for many years. The company produces well-proven drugs "Reduxin" and "Reduxin Forte". They are aimed at reducing weight and restoring metabolic health, thereby minimizing such dangerous complications of obesity as cardiovascular disasters, the development of type 2 diabetes, decreased fertility, impaired functions of the musculoskeletal system, and a number of others. Enligria, Quinliro and Quincenta drugs expand the toolkit for doctors and make effective therapy and prevention of a number of socially significant diseases accessible and personalized for every patient in Russia, regardless of gender, age and the presence of concomitant diseases.

The development and market launch of new medicines in various nosologies is one of the key areas of research and technological development of the Promomed Group of Companies. In recent years, a special focus has been on the development of drugs for the treatment of cancer, hepatitis, HIV, gastroenterological diseases and conditions, and immune response modulators. Biotechnological products have become a separate area of work. In total, more than 100 new drugs are currently at various stages of development and registration.